Funding sources: The PEARL study was supported by Janssen Research & Development, LLC, a Johnson & Johnson pharmaceutical company, Spring House, PA, U.S.A.
A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial
Article first published online: 27 SEP 2012
© 2012 The Authors. BJD © 2012 British Association of Dermatologists
British Journal of Dermatology
Volume 168, Issue 2, pages 444–446, February 2013
How to Cite
Tsai, T.-F., Chiu, H.-Y., Song, M. and Chan, D. (2013), A case of latent tuberculosis reactivation in a patient treated with ustekinumab without concomitant isoniazid chemoprophylaxis in the PEARL trial. British Journal of Dermatology, 168: 444–446. doi: 10.1111/j.1365-2133.2012.11162.x
Conflicts of interest: T-F.T. has conducted clinical trials or received honoraria for serving as a consultant for Wyeth Pharmaceuticals (now Pfizer Inc.), Serono International SA (now Merck Serono SA), Uni-Pharma/Biogen Idec and Janssen-Cilag Pharmaceuticals, and has received speaking fees from Abbott Laboratories. H-Y.C. has no conflicts of interest to declare. M.S. and D.C. are employees of Janssen Biotech, Inc., Spring House, PA, U.S.A., and own stock in the parent company, Johnson & Johnson.
- Issue published online: 30 JAN 2013
- Article first published online: 27 SEP 2012
- Accepted manuscript online: 20 JUL 2012 11:23AM EST